National Center for Tumor Diseases (NCT) Heidelberg
Dr. Nagarajan Paramasivam currently serves as the Workflow Development Lead at the National Center for Tumor Diseases (NCT) Heidelberg, where responsibilities include developing computerized system validation for personalized cancer genomic data analysis workflows and leading a team of researchers. Previously, Dr. Paramasivam was a Senior Bioinformatics Scientist at NCT, focusing on cancer genomics and maintaining workflows for precision oncology programs. Prior experience includes a postdoctoral research fellowship at DKFZ, working on NGS data analysis for rare genetic diseases and cancer predisposition, and a PhD project at the Max Planck Institutes concentrating on vaccine development against Gram-negative bacteria. Educational qualifications include a Doctor of Science from the Max Planck Institute, a Master’s in Bioinformatics from Bharathiar University, and a Bachelor’s in Zoology with a specialization in Biotechnology.
This person is not in any teams
National Center for Tumor Diseases (NCT) Heidelberg
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), Heidelberg University Hospital and German Cancer Aid. The NCT's goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here the patients benefit from an individual treatment plan prepared in a timely manner in interdisciplinary expert rounds, the so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. Since 2015, a second site for the NCT beside Heidelberg has been under development in Dresden.